)
Eledon Pharmaceuticals (ELDN) investor relations material
Eledon Pharmaceuticals Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Tegoprubart, an anti-CD40L antibody, remains the focus of development in kidney and islet transplantation; no products are approved and no product sales revenue has been generated.
Q3 net loss narrowed to $3.9M from $17.5M, mainly due to a $17.0M non-cash warrant-liability fair-value gain; operating expenses increased to $21.7M.
Kidney-transplant extension data showed higher eGFR with tegoprubart than tacrolimus through month 24; planned registrational trials remain dependent on additional financing.
Financial highlights
Q3 R&D expense was $17.8M vs. $15.0M a year earlier; G&A was $3.9M vs. $4.1M, and operating expenses totaled $21.7M vs. $19.1M.
Q3 net loss was $3.9M, or $0.03 per share, vs. $17.5M, or $0.21 per share; excluding warrant fair-value changes, Q3 net loss was $21.0M vs. $18.0M.
9M operating expenses were $65.7M vs. $61.8M, and net loss was $74.6M vs. $35.2M; warrant remeasurement shifted from a $22.9M gain to an $11.6M loss.
9M operating cash use was $64.3M vs. $48.3M; quarter-end cash and equivalents were $6.9M, while cash, equivalents and short-term investments totaled $69.7M.
Outlook and guidance
Global Phase 3 LEGACY in kidney transplantation is planned for Q4 2026, subject to financing; expected enrollment is ~600, with a week-52 non-inferiority endpoint based on BPAR, graft loss and death.
FDA cleared the IND for a planned company-sponsored registrational-path islet-transplant study; initiation requires additional financing.
Other planned programs include an investigator-led de novo liver-transplant study; FDA guidance on the kidney xenotransplantation path to market is anticipated over the next 12 months.
Manufacturing and personnel costs are expected to rise as kidney Phase 3 and islet programs advance; current resources are not expected to fund planned operations for at least 12 months from financial-statement issuance.
- Tegoprubart shows superior efficacy and safety over tacrolimus in transplant trials.ELDN
Corporate presentation - Net loss rose to $31.6M in Q2 2026; strong clinical data but further funding required.ELDN
Q2 2026 - Phase 2 kidney transplant data and islet cell trial results expected next year, backed by strong funding.ELDN
Guggenheim Securities Inaugural Healthcare Innovation Conference - Tegoprubart advances with robust transplant data, global trials, and broad expansion potential.ELDN
Leerink’s Global Healthcare Conference 2025 - Tegoprubart delivers superior kidney function, safety, and quality of life compared to tacrolimus.ELDN
Study result - Tegoprubart achieved key clinical results; Q1 2026 net loss $39.0M, cash runway into Q2 2027.ELDN
Q1 2026 - Biotech firm seeks to raise up to $500M, including $75M at-the-market, for immunology R&D.ELDN
Registration filing - Shareholders will vote on director elections, share authorization, and auditor ratification.ELDN
Proxy filing - Shareholders will vote on director elections, stock authorization increase, and auditor ratification.ELDN
Proxy filing
Next Eledon Pharmaceuticals earnings date
Next Eledon Pharmaceuticals earnings date
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
)
)